tiprankstipranks
Neurocrine’s Schizophrenia Drug Excels in Phase 2 Trials
Company Announcements

Neurocrine’s Schizophrenia Drug Excels in Phase 2 Trials

Don't Miss our Black Friday Offers:

Neurocrine (NBIX) has issued an update.

Neurocrine Biosciences, Inc. revealed promising top-line results from a Phase 2 clinical trial of NBI-1117568, a novel oral treatment for schizophrenia, which met its primary endpoint with significant improvements in symptom scores. The medication, which targets the muscarinic M4 receptor, showed a favorable safety profile, with adverse events comparable to placebo. Following these positive outcomes, Neurocrine plans to progress NBI-1117568 into Phase 3 trials, bolstering its portfolio of muscarinic receptor-focused therapies.

For a thorough assessment of NBIX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyEvercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive
TheFlyNeurocrine’s Ingrezza shows efficacy in Huntington’s Disease Chorea
TheFlyNeurocrine presents data from Ingrezza studies on tardive dyskines patients
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App